Hairy cell leukemia
Drug research and approvals for hairy cell leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 14 studies of hairy cell leukemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 1 drug trials for it since 2013, and FDA has 2 approved and 3 open orphan designations naming it.
- Recruiting worldwide: 14
- Trials authorized in Canada: 1
- FDA orphan approvals: 2
- EU medicines: 0
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell LeukemiaNCT06965114 · Phase 1 / Phase 2 · National Cancer Institute (NCI) · starts May 29, 2026
- Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve…NCT06774677 · Not reported · IRCCS Azienda Ospedaliero-Universitaria di Bologna · starts Dec 12, 2024
- Hairy Cell Leukemia: Harnessing the Full Power of Extracellular Vesicles to Improve Patient Care ManagementNCT06764524 · Not reported · IRCCS Azienda Ospedaliero-Universitaria di Bologna · starts Dec 5, 2024
- A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)NCT06561360 · Phase 2 · Memorial Sloan Kettering Cancer Center · starts Sep 9, 2024
- AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell LymphomasNCT06340737 · Phase 1 · Stanford University · starts Mar 29, 2024
- Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and…NCT04815356 · Phase 1 · National Cancer Institute (NCI) · starts May 23, 2022
- Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.NCT04775745 · Phase 1 · Newave Pharmaceutical Inc · starts Jul 19, 2021
- Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and VariantNCT04322383 · Phase 2 · National Cancer Institute (NCI) · starts Jan 7, 2021
- Hairy Cell Leukemia Patient Data RegistryNCT02560883 · Not reported · Ohio State University Comprehensive Cancer Center · starts Jan 2, 2013
Approved 4
- Moxetumomab pasudotoxCD22 binding agent
- CladribineDNA inhibitor
- PentostatinAdenosine deaminase inhibitor
- Interferon alfa-2bInterferon alpha/beta receptor agonist
Phase 2 12
- RituximabB-lymphocyte antigen CD20 binding agent
- VemurafenibSerine/threonine-protein kinase B-raf inhibitor
- AcetaminophenCyclooxygenase inhibitor
- DiphenhydramineHistamine H1 receptor antagonist
- BinimetinibDual specificity mitogen-activated protein kinase kinase 1 inhibitor
- Interferon alfa-2aInterferon alpha/beta receptor agonist
- ObinutuzumabB-lymphocyte antigen CD20 binding agent
- BendamustineDNA inhibitor
- EpinephrineAdrenergic receptor agonist
- EncorafenibSerine/threonine-protein kinase B-raf inhibitor
- BL22CD22 binding agent
- LMB-2Interleukin-2 receptor alpha chain binding agent
Phase 1 or earlier 4
- FamotidineHistamine H2 receptor antagonist
- DexamethasoneGlucocorticoid receptor agonist
- AspirinCyclooxygenase inhibitor
- PlixorafenibSerine/threonine-protein kinase B-raf inhibitor
How its trials ended
105 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 35 whose ending is known, 34% met their primary endpoint, 0% missed it and 66% stopped early.
- Completed, result not reported3937%
- Ongoing2928%
- Met its primary endpoint1211%
- Stopped: other or unclear1110%
- Stopped: enrollment or feasibility77%
- Stopped: sponsor or business decision33%
- Stopped: funding22%
- Status unknown22%
| Authorized | Trial | Sponsor | Status |
|---|---|---|---|
| Jan 9, 2015 | A pivotal multicenter trial of moxetumomab pasudotox in relapsed/refractory hairy cell leukemiaCAT-8015 (moxetumomab pasudotox) | MedImmune LLC | Ongoing |
| Feb 26, 1993 | Leustatin InjectionTreatment of hairy cell leukemia. | R. W. Johnson Pharmaceutical Research Institute | Approved |
| Oct 11, 1991 | NipentSingle agent treatment for adult patients with alpha-interferon-refractory hairy cell leukemia. | SuperGen, Inc. | Approved |
| May 16, 2008 | BlinatumomabTreatment for hairy cell leukemia. | Amgen, Inc. | Designated |
| Aug 10, 2004 | (1S)-1-(9-deazahypoxanthin-9-yl)-1,4-dideoxy-1,4-imino-D-rib…Treatment of chronic lymphocytic leukemia and related leukemias to include prolymphocytic leukemia, adult T-cell leukemia, and hairy cell… | Mundipharma Research Ltd. | Designated |
| May 3, 1990 | Granulocyte macrophage-colony stimulating factorTreatment of neutropenia due to hairy cell leukemia. | Schering Corporation | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA